CIRMEN

Published on May 28, 2020 – Updated on May 28, 2020



The CIRMEN (Centre d'Innovation et de Recherche en Médicine Nucléaire) created by CCC in 2016, in close
interaction with our UMR Inserm/UdA should be highlightened as being devoted to GMP production, formulation and quality control of radiopharmaceuticals for first into human. Such a structure dedicated to *fisrt into human* clinical transfer is rare in France and open many researches perspectives in radiopharmaceuticals for imaging and targeted therapy. As example, from 2018 CIRMEN is one of the French centers involved in the clinical transfer of 177Lu-PSMA for theranostic management of patients with prostate cancer.

Responsable

Dr Sophie LEVESQUE(mailto:Sophie%2ELEVESQUE%40uca%2Efr?Subject=&body=)

Membres

Pr Florent CACHIN(mailto:florent%2Ecachin%40clermont%2Eunicancer%2Efr)

Dr Philippe AUZELOUX(mailto:philippe%2Eauzeloux%40uca%2Efr)

https://imost.uca.fr/version-francaise/plateformes/cirmen/cirmen-1(https://imost.uca.fr/version-francaise/plateformes/cirmen/cirmen-1)